rs137868995
Positions:
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 10P and 2B. PM1PP5_Very_StrongBP4BS2_Supporting
The NM_001080483.3(MYMK):c.271C>A(p.Pro91Thr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00192 in 1,613,944 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.0012 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0020 ( 2 hom. )
Consequence
MYMK
NM_001080483.3 missense
NM_001080483.3 missense
Scores
2
7
9
Clinical Significance
Conservation
PhyloP100: 9.28
Genes affected
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
PM1
?
In a chain Protein myomaker (size 220) in uniprot entity MYMK_HUMAN there are 10 pathogenic changes around while only 1 benign (91%) in NM_001080483.3
PP5
?
Variant 9-133519002-G-T is Pathogenic according to our data. Variant chr9-133519002-G-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 430839.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr9-133519002-G-T is described in Lovd as [Pathogenic]. Variant chr9-133519002-G-T is described in Lovd as [Likely_pathogenic].
BP4
?
Computational evidence support a benign effect (MetaRNN=0.02295518). . Strength limited to SUPPORTING due to the PP5.
BS2
?
High Homozygotes in GnomAdExome4 at 2 AR geneVariant has number of homozygotes lower than other variant known as pathogenic in the gene, so the strength is limited to Supporting.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
MYMK | NM_001080483.3 | c.271C>A | p.Pro91Thr | missense_variant | 3/5 | ENST00000339996.4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
MYMK | ENST00000339996.4 | c.271C>A | p.Pro91Thr | missense_variant | 3/5 | 2 | NM_001080483.3 | P1 | |
MYMK | ENST00000413714.1 | n.326C>A | non_coding_transcript_exon_variant | 3/4 | 3 |
Frequencies
GnomAD3 genomes ? AF: 0.00124 AC: 189AN: 152166Hom.: 0 Cov.: 32
GnomAD3 genomes
?
AF:
AC:
189
AN:
152166
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00124 AC: 311AN: 250752Hom.: 0 AF XY: 0.00122 AC XY: 165AN XY: 135548
GnomAD3 exomes
AF:
AC:
311
AN:
250752
Hom.:
AF XY:
AC XY:
165
AN XY:
135548
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00199 AC: 2905AN: 1461660Hom.: 2 Cov.: 31 AF XY: 0.00196 AC XY: 1425AN XY: 727108
GnomAD4 exome
AF:
AC:
2905
AN:
1461660
Hom.:
Cov.:
31
AF XY:
AC XY:
1425
AN XY:
727108
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? AF: 0.00124 AC: 189AN: 152284Hom.: 0 Cov.: 32 AF XY: 0.00106 AC XY: 79AN XY: 74458
GnomAD4 genome
?
AF:
AC:
189
AN:
152284
Hom.:
Cov.:
32
AF XY:
AC XY:
79
AN XY:
74458
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
7
ALSPAC
AF:
AC:
8
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
23
ExAC
?
AF:
AC:
155
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:9Uncertain:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Congenital nonprogressive myopathy with Moebius and Robin sequences Pathogenic:5Uncertain:1
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | May 06, 2021 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with Carey-Fineman-Ziter syndrome (MIM#254940). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0200 - Variant is predicted to result in a missense amino acid change from proline to threonine. (I) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD (v2) <0.01 for a recessive condition (341 heterozygotes, 0 homozygotes). (SP) 0309 - An alternative amino acid change at the same position has been observed in gnomAD (v3) (2 heterozygotes, 0 homozygotes). (I) 0502 - Missense variant with conflicting in silico predictions and very high conservation. (I) 0604 - Variant is not located in an established domain, motif, hotspot or informative constraint region. (I) 0705 - No comparable missense variants have previous evidence for pathogenicity. (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. The variant has previously reported in many individuals with Carey-Fineman-Ziter syndrome (MIM#254940) (ClinVar, PMID: 28681861, 29560417). (SP) 0901 - This variant has strong evidence for segregation with disease. The variant has been reported to segregate with disease in at least five families (PMID: 28681861, PMID: 30065953) (SP) 1002 - This variant has moderate functional evidence supporting abnormal protein function. The variant is considered to be hypomorphic as it results in a partial loss of function rather than a null allele (PMID: 28681861). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 07, 2019 | - - |
Uncertain significance, flagged submission | clinical testing | Baylor Genetics | Jul 18, 2019 | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 02, 2022 | Variant summary: MYMK c.271C>A (p.Pro91Thr) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0012 in 282106 control chromosomes, found exclusively in the heterozygous state, and predominantly at a frequency of 0.0022 within the Non-Finnish European subpopulation in the gnomAD database. c.271C>A has been reported in the literature in the compound heterozygous state in at least 10 individuals affected with Congenital Nonprogressive Myopathy With Moebius And Robin Sequences (Carey-Fineman-Ziter Syndrome) from 5 different families in which the variant segregrated with the disease phenotype (e.g. Di Gioia_2017, Hedberg-Oldfors_2018). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function (Di Gioia_2017). These results indicated that the variant results in a partial loss of function, as observed in a zebrafish model, and has reduced protein expression in in vitro experiments but retains residual function upon overexpression. As a result of these experimental findings, it has been proposed that c.271C>A is likely a hypomorphic variant. Eight submitters have provided clinical-significance assessments for this variant to ClinVar after 2014 with conflicting assessments. The majority have classified the variant as either pathogenic (n=4) or likely pathogenic (n=2), and the remaining have classified it as VUS (n=2). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 05, 2019 | The MYMK c.271C>A (p.Pro91Thr) variant is a missense variant that has been reported in three studies and is found in a total of 11 individuals from six families with phenotypes overlapping Carey-Fineman-Ziter syndrome, all carrying the variant in a compound heterozygous state with a second missense variant (Di Gioia et al. 2017; Alrohaif et al. 2018; Hedberg-Oldfors et al. 2018). Individuals ranged in age from one to 69 years and the main phenotypes included facial muscle weakness, motor delays, generalized muscle hypoplasia, congenital contractures, hypermobility, myopathy noted through electromyography, growth failure, feeding problems, skeletal features including scoliosis and short stature, and facial and head features including broad nasal tip, micrognathia or retrognathia, lagophthalmos, ptosis, high palate, cleft palate, and a thin tubular neck. Parents were also genotyped in five of the families, showing an unaffected parent carrying the variant in a heterozygous state (Di Gioia et al. 2017; Hedberg-Oldfors et al. 2018). Control data are unavailable for this variant, which is reported at a frequency of 0.002192 in the European (non-Finnish) population of the Genome Aggregation Database. Functional studies showed an effect on protein stability in HeLa cells and lower expression levels in C2C12 cells with FLAG-tagged human p.Pro91Thr constructs. However, presence of this variant did not affect myoblast fusion. In zebrafish studies, the p.Pro91Thr variant partially rescued the phenotype, whereas there was complete rescue with wild-type mRNA (Di Gioia et al. 2017). Based on the collective evidence, the p.Pro91Thr variant is classified as pathogenic for Carey-Fineman-Ziter syndrome. - |
Likely pathogenic, criteria provided, single submitter | research | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Dec 03, 2018 | The heterozygous p.Pro91Thr variant in TMEM8C was identified by our study in the compound heterozygous state, with a VUS, in one individual with Carey-Finteman-Ziter syndrome. This variant has been identified in 0.1186% (328/276516) of chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs137868995). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a recessive carrier frequency. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. The p.Pro91Thr variant in MYMK has been reported in 7 Caucasian individuals from the US and New Zealand with Carey Finteman-Ziter syndrome and segregated with disease in 6 affected relatives from 3 families (PMID: 28681861). The presence of this variant in combination with 3 variants reported pathogenic by OMIM in ClinVar and in 7 individuals with Carey-Finteman-Ziter syndrome increases the likelihood that the p.Pro91Thr variant is pathogenic. In vitro functional studies provide some evidence that the p.Pro91Thr variant may impact, but not eliminate, myoblast fusion activity (PMID: 28681861). However, these types of assays may not accurately represent biological function. In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic. ACMG/AMP Criteria applied: PM2, PM3, PP1, PS3_Supporting (Richards 2015). - |
Carey-Fineman-Ziter syndrome 1 Pathogenic:3
Likely pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jun 30, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Molecular Genetics, Royal Melbourne Hospital | Nov 30, 2020 | This sequence change is predicted to replace proline with threonine at codon 91 of the MYMK protein (p.(Pro91Thr)). The proline residue is invariant across species (100 vertebrates, UCSC), and is located in a domain of unknown function. There is a small physicochemical difference between proline and threonine. The variant is present in a large population cohort at a frequency of 0.1% (rs137868995, 341/282,106 alleles, 0 homozygotes in gnomAD v2.1). The variant has been identified with a second allele in at least six individuals with congenital nonprogressive myopathy with Moebius and Robin sequences, and segregates in affected siblings in multiple families (PMID: 28681861, 29560417, 30065953). The variant is a hypomorph, and the fusogenic activity of the mutant protein is fully/partially rescued in a zebrafish model (PMID: 28681861). Multiple lines of computational evidence have conflicting predictions for the missense substitution (3/6 algorithms predict deleterious). Based on the classification scheme RMH ACMG Guidelines v1.2.1, this variant is classified as PATHOGENIC. Following criteria are met: PM3_Strong, PP1_Strong, PS3_Supporting. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Nov 20, 2023 | - - |
MYMK-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Dec 18, 2023 | The MYMK c.271C>A variant is predicted to result in the amino acid substitution p.Pro91Thr. This variant has been reported in the compound heterozygous state in multiple individuals with Carey-Fineman-Ziter syndrome (Figure S1, Di Gioia et al. 2017. PubMed ID: 28681861; Alrohaif et al. 2018. PubMed ID: 29560417; Hedberg-Oldfors et al. 2018. PubMed ID: 30065953). This variant is reported in 0.22% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant is interpreted as pathogenic. - |
not provided Uncertain:1
Uncertain significance, flagged submission | clinical testing | GeneDx | Apr 03, 2023 | In silico analysis supports that this missense variant does not alter protein structure/function, and published functional studies suggest residual protein activity is more similar to wild type activity than to null allele activity (Di Gioia et al., 2017); This variant is associated with the following publications: (PMID: 7131178, 28681861, 30065953, 29560417, 32573669, 32333597, 32528171) - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D
M_CAP
Benign
D
MetaRNN
Benign
T
MetaSVM
Benign
T
MutationTaster
Benign
D
PrimateAI
Uncertain
T
PROVEAN
Benign
N
REVEL
Uncertain
Sift
Benign
T
Sift4G
Pathogenic
D
Polyphen
D
Vest4
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at